Elucidating the Mechanisms of Hugan Buzure Granule in the Treatment of Liver Fibrosis via Network Pharmacology

Table 3

Docking results of the top 5 hub targets with active compounds.

No.	Compound	Affinity (kJ·mol^−1)
		IL6	CASP3	EGFR	VEGF	MAPK
1	Dl-3n-butylphthalide	−5.4	−5.2	−6.4	−5.3	−8.5
2	Esculetin	−6.0	−5.1	−7.2	−5.3	−6.7
3	Apigenin	−6.4	−6.4	−8.2	−6.8	−9.0
4	Luteolin	−6.6	−6.8	−8.4	−7.1	−8.9
5	Luteolin-7-o-glucoside	−7.5	−7.6	−10.0	−7.2	−9.2
6	Poriferast-5-en-3beta-ol	−5.5	−6.7	−8.2	−5.7	−7.7
7	Beta-sitosterol	−5.7	−6.4	−9.1	−5.8	−7.7
8	Delphinidin	−6.6	−6.6	−8.7	−7.4	−8.5
9	Eseramine	−7.1	−6.5	−7.6	−6.1	−8.1
10	2S, 2’S-aurantiamide acetate	−6.6	−7.0	−9.0	−6.2	−7.8
11	Lactucopicrin	−6.0	−8.0	−9.2	−6.3	−7.9
12	(2R)-3-[3-(5-allyl-2-hydroxyphenyl)-4-hydroxyphenyl]propane-1, 2-diol	−6.2	−6.6	−8.0	−6.0	−8.1
13	Gitoxigenin	−6.2	−6.8	−8.5	−6.0	−7.2
14	Cyanidin 3-glucoside	−6.4	−6.1	−8.5	−7.3	−8.6
15	Ammidin	−6.0	−6.1	−8.2	−6.7	−8.0
16	Stigmasterol	−6.2	−6.6	−8.5	−6.9	−8.0
17	Sesamin	−7.2	−7.3	−9.7	−7.1	−9.5
18	NSC63551	−6.4	−7.2	−9.3	−5.9	−8.3
19	Isorhamnetin	−6.5	−6.7	−8.3	−6.8	−8.8
20	Kaempferol	−6.4	−6.4	−8.0	−6.7	−8.8
21	Campest-5-en-3beta-ol	−6.1	−6.1	−9.1	−5.5	−7.5
22	Isofucosterol	−5.8	−6.5	−9.5	−5.8	−7.9
23	Matrine	−5.7	−6.0	−6.7	−5.5	−7.4
24	CLR	−5.3	−6.3	−7.8	−5.8	−7.3
25	Quercetin	−6.5	−6.8	−8.5	−7.2	−8.5